The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma
M. Chesnokov, I. Khan, Y. Park, J. Ezel, G. Mehta, A. Yousif, L. Hong, R. J. Buckanovich, I. Chefetz Menaker
This study investigates MEK1/2 pathway activity in high-grade serous ovarian carcinoma and shows that its inhibition reduces tumor growth but promotes stem-like properties, suggesting potential resistance mechanisms.
bioRxiv · Sep 16, 2019Cancer Biology